Atripla (HIV)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Atripla (efavirenz/emtricitabine/tenofovir) 23
6.1 Overview 23
6.2 Efficacy 25
6.3 Safety 26
6.4 SWOT Analysis 26
6.5 Forecast 29
7 Appendix 30
7.1 Bibliography 30
7.2 Abbreviations 32
7.3 Methodology 34
7.4 Forecasting Methodology 34
7.4.1 HIV Prevalence 34
7.4.2 Percent Drug-Treated Patients 34
7.4.3 General Pricing Assumptions 35
7.4.4 Individual Drug Assumptions 36
7.4.5 Generic Erosion 36
7.5 Physicians and Specialists Included in this Study 37
7.5.1 Survery of Prescribing Physicians 38
7.6 About the Authors 39
7.6.1 Authors 39
7.6.2 Global Head of Healthcare 40
7.7 About GlobalData 41
7.8 Contact Us 41
7.9 Disclaimer 41